• Oncotelic’s PDAOAI platform indexes 125,000+ PubMed abstracts on TGF-β signaling, enabling researchers to interrogate the evidence for testable, auditable hypotheses rather than rely on black-box predictions.
• Recent industry coverage places Oncotelic alongside Rockwell Automation, Emerson Electric, Thermo Fisher Scientific, and Danaher as contributors to the pharmaceutical sector’s shift toward AI-integrated operations.
• The hypothesis-first approach addresses a core challenge in biotech research: reducing training-set bias and building transparent, reproducible chains from question to evidence to hypothesis.

Pharmaceutical research and manufacturing are undergoing a structural transition. Regulatory agencies are raising expectations around data integrity and traceability, while the industry is shifting from retrospective audits toward continuous, AI-enabled monitoring systems. At the same time, drug discovery is being reshaped by the growing availability of large-scale biomedical data and the tools to interrogate it at scale. Both shifts reflect a common underlying reality: manual processes and isolated datasets are no longer sufficient in an environment where scientific literature expands rapidly and regulatory expectations demand continuous, defensible documentation. Oncotelic Therapeutics (OTCQB: OTLC) has responded to this environment with PDAOAI, an evidence-interrogation platform designed to surface testable research hypotheses from the global TGF-β literature.

What PDAOAI Does Differently

Instead of relying on traditional predictive models trained to replicate historical datasets, PDAOAI takes a retrieval-and-interrogation approach. The platform organizes and connects large volumes of biomedical literature, enabling researchers to identify patterns and generate testable hypotheses with direct links to underlying source data.

Each output is tied back to its originating evidence, creating an auditable chain from question to evidence to hypothesis. This distinction is increasingly relevant as concerns grow around model transparency, reproducibility, and training-set bias in biomedical AI. By positioning itself as an interrogation layer rather than a black-box predictor, Oncotelic is aligning its platform with the practical requirements of research environments where every conclusion must be validated and defensible.

The TGF-β Corpus

The platform’s initial deployment focuses on a corpus of more than 125,000 PubMed abstracts centered on transforming growth factor beta (“TGF-β”), a signaling pathway implicated in cancer progression, immune response, fibrosis, and metabolic disease. TGF-β is also the scientific foundation of Oncotelic’s lead therapeutic candidate, OT-101, a first-in-class anti-TGF-β RNA-based therapy.

By structuring and analyzing this body of literature, PDAOAI allows researchers to move beyond keyword searches to explore relationships across datasets, identifying recurring biological patterns and potential mechanistic links that may inform future development strategies.

A Broader Industry Transition

The context for Oncotelic’s platform extends beyond drug discovery. A recent editorial positioned the company within a broader group of organizations contributing to the integration of artificial intelligence across pharmaceutical and life sciences operations. This group includes Rockwell Automation Inc., Emerson Electric Co., Thermo Fisher Scientific Inc., and Danaher Corp., each advancing AI-enabled systems across industrial and laboratory environments.

Parallel developments are taking place in manufacturing. Nightfood Holdings Inc., operating as TechForce Robotics, has advanced AI-enabled robotic systems designed to automate sterile manufacturing environments, reinforcing the industry’s shift toward integrated, real-time compliance systems.

Together, these developments reflect a wider transition toward interconnected, intelligent systems across the pharmaceutical value chain, spanning both research and production.

Why the Positioning Matters

Regulatory frameworks such as the European Union’s updated GMP Annex 1 and initiatives from the U.S. Food and Drug Administration are encouraging the adoption of continuous monitoring, embedded intelligence, and automated documentation. These changes are contributing to what is increasingly described as Pharma 4.0, an environment where data flows continuously across systems and compliance is integrated into every stage of the process.

While PDAOAI operates at the discovery and hypothesis-generation stage rather than in manufacturing, the underlying principle is consistent: replacing fragmented, manual processes with systems that are continuously auditable, reproducible, and resistant to bias.

For Oncotelic, this positioning connects its therapeutic pipeline, including OT-101 and its focus on rare and underserved indications, to a broader infrastructure shift occurring across the industry.

Closing Perspective

As artificial intelligence continues to expand across both discovery and manufacturing environments, platforms that enable traceable, reproducible, and evidence-based decision-making are becoming central to pharmaceutical development.

Within this evolving framework, PDAOAI reflects a model focused not on prediction alone, but on structured interrogation of the underlying evidence – a distinction that may become more important as the industry places greater emphasis on transparency, validation, and data integrity.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) and may include paid advertising.

• Planet Ventures is increasing its exposure to AI-driven space infrastructure through strategic investment in Antaris
• The company is positioning itself at the intersection of orbital computing, satellite software, and the next frontier
• These moves underscore a broader industry shift toward space-based data infrastructure and lunar-enabling technologies

Planet Ventures (CSE: PXI) (OTC: PNXPF) (FSE: P6U) is aligning itself with one of the transformative trends in modern technology: the convergence of space infrastructure and artificial intelligence. With global demand for computing power increasing and terrestrial constraints on energy, cooling, and land becoming more pronounced, a new frontier is quickly emerging – orbital data systems and space-based compute networks capable of supporting next-generation AI applications.

Recent developments in the industry highlight the urgency and scale of this transition. For example, SpaceX has recently filed plans for a massive orbital data-center constellation, possibly deploying up to 1 million satellites designed to power AI workloads in space (ibn.fm/FV8XX). This concept leverages solar energy and the vacuum of space for cooling, positioning orbit as a potentially more efficient solution for high-performance computing. SpaceX’s integration with xAI signals a strategic effort to unify AI demand with space-based delivery infrastructure, reinforcing the idea that space could become a foundational layer of the global compute stack (ibn.fm/HLSoo).

While analysts suggest significant economic and engineering challenges ranging from the complexity of maintaining large-scale orbital systems to radiation impacts on hardware, the broader industry consensus is moving from “if” to “when.” Crucially, this evolution is not just limited to low Earth orbit. It is increasingly tied to renewed global interest in lunar development, where resilient communications, real-time data processing, and autonomous systems will be important for sustained human and robotic presence. 

Planet Ventures Inc. is implementing a focused investment strategy targeted at capturing early-stage value in the quickly evolving space economy. In early April, the company made a strategic investment in Antaris, following a $28 Million Series A Financing, a platform that enables full mission virtualization from design to simulation to deployment and operations (ibn.fm/I2pfB). The software-centric approach is quickly becoming vital as satellite constellations become more complex, supporting capabilities such as predictive modeling, anomaly detection, and autonomous mission management.

Operating at the intersection of disruptive innovation and venture capital, Planet Ventures is aligning its portfolio with sectors where automation, AI, and space infrastructure converge. As industry shifts toward orbital computing and lunar-linked technologies, the company’s early positioning reflects a broader strategy to participate in building the foundational infrastructure of not only a multi-trillion-dollar space economy, but the next frontier of technology.

For more information, visit www.PlanetVenturesInc.com.

NOTE TO INVESTORS: The latest news and updates relating to PNXPF are available in the company’s newsroom at https://ibn.fm/PNXPF

Disclaimer

Investor Brand Network (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Planet Ventures Inc. will make aggregate payments of $100,000  to us to provide marketing services for a term of 1 year. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of applicable securities legislation, including statements regarding Planet Ventures’ investment strategy, anticipated market developments, the projected growth of the global space economy, the expected timelines and milestones of portfolio companies including Mantis Space and GRU Space, the anticipated economic impact of Mantis Space’s operations, and the role of Tansu Yegen as strategic advisor. Forward-looking statements are based on the current expectations, estimates, forecasts, and projections of Planet Ventures’ management and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements.

Forward-looking statements are not guarantees of future performance. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this document are made as of the date hereof and Planet Ventures undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

Risk Factors

Investing in Planet Ventures and its portfolio companies involves a high degree of risk. The following is a summary of key risk factors. This is not an exhaustive list, and additional risks may exist that are not currently known:

• Early-Stage Investment Risk. Portfolio companies have limited operating histories and are pre-revenue. Investments are speculative and may result in a total loss of capital.
• Technology Risk. The orbital energy and lunar habitation technologies underlying the Company’s investments are unproven at commercial scale and may not be successfully developed or deployed.
• Regulatory Risk. Space sector operations require licenses and approvals from domestic and international regulatory bodies. Failure to obtain or maintain these could materially delay or prevent operations.
• Market Risk. Commercial demand for in-space power systems and lunar services has not been established at scale. Projected market growth may not be realized within anticipated timeframes.
• Liquidity Risk. Investments in private, early-stage companies are illiquid. There is no guarantee of a market for these securities or the ability to exit on favorable terms.
• Capital Risk. Portfolio companies may require additional funding that may not be available, or may be available only on dilutive or restrictive terms.
• Macroeconomic and Geopolitical Risk. Adverse macroeconomic conditions or geopolitical developments could disrupt the Company’s investment strategy or the operations of portfolio companies.
• Key Personnel Risk. The Company’s performance depends in part on retaining key personnel and advisors. Loss of key individuals could adversely affect the Company’s operations and investment activities

• The scale and impact of cardiovascular disease underscore why innovation in this area is so critical.
• Advances in genomics and epigenetics are making it possible to better understand how genetic predisposition and environmental influences interact to drive disease progression.
• By utilizing a simple blood test, Cardio Diagnostics is lowering barriers to advanced cardiovascular testing.

Cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (“AI”) and multi-omic biomarkers to deliver actionable insights from a simple blood sample, enabling more informed and timely care cardiac care decisions.

The scale and impact of cardiovascular disease underscore why innovation in this area is so critical. According to the Centers for Disease Control and Prevention, heart disease remains the leading cause of death in the United States, responsible for approximately one in every three deaths. Beyond mortality, the economic burden is substantial. In the United States alone, cardiovascular disease costs the healthcare system $233 billion annually in direct medical costs and an additional $185 billion in lost productivity, with total costs projected to approach $2 trillion by 2050. These numbers highlight the importance of improving both prevention and treatment strategies.

Despite advances in medicine, a key challenge in managing cardiovascular disease is that it often develops silently over many years before symptoms appear. Traditional risk assessment tools rely heavily on clinical factors such as cholesterol levels, blood pressure and lifestyle indicators. While useful, these measures can fail to capture the underlying biological changes that can precede disease onset. Studies indicate that many cardiovascular risks and related conditions remain undiagnosed or unrecognized, with significant gaps in screening leaving large portions of at-risk individuals unidentified, underscoring limitations in current risk assessment approaches.

This gap has driven increasing interest in precision medicine approaches that incorporate molecular-level data to improve risk prediction and help guide treatment. Advances in genomics and epigenetics are making it possible to better understand how genetic predisposition and environmental influences interact to drive disease progression. Cardio Diagnostics is applying these principles through its proprietary platform, which combines epigenetic and genetic biomarkers with artificial intelligence to generate personalized cardiovascular insights. The company’s platform is designed to analyze molecular signals captured in a blood sample and translate them using AI into clinically relevant information that can support earlier intervention and more targeted treatment planning.

One of the key advantages of this approach is its ability to detect biological changes before they may manifest as clinical symptoms. Epigenetic markers, such as DNA methylation patterns, can reflect the cumulative impact of lifestyle, environmental exposures and disease processes on gene expression. Research has shown that these markers can serve as early indicators of disease risk, providing a window of opportunity for preventive action.

Artificial intelligence plays a central role in making sense of this complex data. Machine learning algorithms can analyze large, multidimensional datasets to identify patterns associated with disease risk and progression. Studies report that AI has the potential to improve diagnostic accuracy and enable more personalized care by uncovering relationships that are not readily apparent through traditional methods. By applying AI to integrated genetic and epigenetic data, Cardio Diagnostics aims to provide clinicians with more precise and actionable insights.

Another important aspect of the company’s platform is its accessibility. By utilizing a simple blood test, Cardio Diagnostics is lowering barriers to advanced cardiovascular testing. This is particularly relevant in the context of ongoing efforts to expand preventive care and improve patient engagement. Blood-based diagnostics can be more easily incorporated into routine clinical workflows, enabling broader adoption and more consistent monitoring over time.

The ability to generate personalized insights also has implications for treatment. Rather than relying on generalized markers, clinicians can use patient-specific molecular data to tailor interventions, potentially improving outcomes and reducing unnecessary treatments. This aligns with a broader shift in healthcare toward individualized care models that prioritize both effectiveness and efficiency.

In addition to supporting early detection, platforms such as the one developed by Cardio Diagnostics may also play a role in ongoing disease management. By tracking molecular changes over time, clinicians can gain a better understanding of how a patient is responding to treatment and adjust as needed. This dynamic approach reflects an evolving view of cardiovascular care as a continuous process rather than a series of isolated events.

As the health-care industry continues to embrace data-driven approaches, the integration of multi-omic biomarkers and AI is expected to become increasingly important. Cardio Diagnostics Holdings is contributing to this transformation by developing tools that aim to bridge the gap between early detection and effective treatment. By providing deeper insights into the biological drivers of cardiovascular disease, the company is helping to support a more proactive and personalized approach to care.

For more information, visit www.CDIO.ai.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

• Safe Pro Group recently began the commercial rollout of NODE-X, a next-gen miniaturized AI-powered edge compute processor of drone footage for threat detection.
• The rollout began at a U.S. Army Exercise, and NODE-X is scheduled to be a part of additional U.S. Army exercises throughout the second quarter of 2026.
• NODE-X is powered by Safe Pro’s patented Safe Pro Object Threat Detection (“SPOTD”), a powerful technology used to rapidly analyze drone imagery and video to identify and detect small explosive threats.

Safe Pro Group (NASDAQ: SPAI), a developer of AI-enabled security, defense, and situational awareness solutions, recently started the commercial rollout of NODE-X at a U.S. Army exercise (https://ibn.fm/5IdSl).

Node-X is a next-gen miniaturized AI-powered edge compute processor of drone footage for detecting threats in military support missions. This solution is the next generation of Safe Pro’s AI-powered ecosystem of tools that enable the rapid processing of drone images and videos for AI threat detection, 3D mapping, and route guidance.

The Node-X is designed as a backpack-sized kit that includes real-time AI inference on an edge compute server, as well as rugged GPU laptops running Safe Pro’s OnSight application, which is compatible with U.S. Army-approved short-range recon (“SRR”) drones.

Node-X is powered by Safe Pro’s Safe Pro Object Threat Detection (“SPOTD”), which is a platform that rapidly analyzes videos and images from virtually any drone to detect and classify explosive threats and other small objects of interest. 

The platform converts raw video into high-resolution 2D/3D models that can quickly be shared to support operational decision-making and provide better situational awareness.

Node-X uses AI and machine learning algorithms that are trained on one of the world’s largest imagery datasets from Ukraine, which includes 2.6 million drone images and 47,000 confirmed detections of small threats like landmines, cluster munitions, ambush drones, and unexploded ordnance (“UXO”).

It operates on the edge without any need for connectivity and incorporates AI-detected threats with the fast generation of 3D models and digital surface models, such as terrain slope, vegetation height, and more.

The field-deployable design and intuitive interface of the solution provides both soldiers and military commanders with important situational awareness, which makes it an ideal piece of tech for a variety of different missions.

The Node-X is scheduled to take part in additional U.S. Army exercises through the second quarter of 2026, as Safe Pro builds momentum towards rapid expansion.

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group is a mission-driven tech company that develops and delivers advanced AI-powered security and defense solutions to customers in the law enforcement, defense, homeland security, and humanitarian industries. At the core of Safe Pro’s mission is a patented computer vision software technology used to rapidly and accurately detect small threats and objects in drone photos and videos, to boost the safety of field operations for ground teams.

For more information, visit Safe Pro Group’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Integrated geochemical and geophysical data point to structurally controlled mineralization at Atikokan rare earth property.
• Dashwa Gneiss Complex emerges as the primary focus for follow-up work.
• Soil, rock, and sediment sampling indicate consistent rare earth element (“REE”) anomalies.
• Results support a coherent exploration model rather than isolated occurrences.
• The project aligns with rising strategic demand for domestic REE supply in North America.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company focused on rare earth projects across North America, has refined its exploration strategy at the Atikokan Rare Earth Property in northwestern Ontario, identifying priority target zones following a comprehensive integration of geochemical assays and geophysical data. The findings mark a shift from early-stage sampling toward more targeted exploration planning (https://ibn.fm/hbas0).

The company’s latest interpretation combines results from rock, soil, and sediment sampling with airborne magnetic and radiometric surveys conducted in 2025. This dataset has enabled Powermax to delineate zones where rare earth element (“REE”) mineralization may be structurally concentrated, rather than dispersed.

Two distinct geological environments have been identified across the property. The Dashwa Gneiss Complex, covering Blocks B and C, has been prioritized for follow-up exploration. In contrast, the White Otter Batholith, designated as Block A, has been assigned lower priority due to weaker geochemical correlations and more diffuse mineralization patterns.

Sampling results provide the basis for this distinction. Rock samples returned total rare earth oxide (“TREO”) values ranging from 19.1 to 503.3 parts per million, with several readings exceeding 200 ppm. Soil samples showed values up to 615.8 ppm, while sediment samples indicated downstream dispersion of REE-bearing material. These figures fall within ranges typically associated with early-stage exploration systems but show consistent anomaly clustering.

More significant for exploration planning is the spatial relationship of these anomalies. Elevated REE values appear linked to structural corridors, shear zones, and lithological contacts: features that can act as conduits for mineralizing processes. This pattern supports a structurally controlled model, where mineralization is concentrated along deformation zones rather than evenly distributed.

The company’s interpretation also highlights geochemical associations between REEs, thorium, and uranium. Such correlations are commonly used as vectors in rare earth exploration, helping geologists trace surface anomalies back to potential subsurface concentrations. In this case, the presence of minerals such as monazite and allanite, both known hosts for light rare earth elements, reinforces the working model.

The technical work underpinning these findings is extensive. The 2025 program included airborne surveys flown at 50-metre line spacing, along with ground-based mapping, prospecting, and systematic sampling. A total of 426 samples were collected and analyzed by AGAT Laboratories Ltd. using sodium peroxide fusion and ICP-OES/MS methods, providing near-total digestion for REE analysis. Quality control procedures included duplicates, blanks, and standards to ensure data reliability.

Powermax’s approach reflects a broader trend in early-stage mineral exploration, where integrated datasets are used to reduce geological uncertainty before advancing to more capital-intensive drilling campaigns. By combining multiple data types, companies aim to increase the probability of targeting zones with meaningful mineralization.

The strategic context for rare earth elements adds another layer of relevance. Global demand for REEs, critical components in electric vehicles, wind turbines, and advanced electronics, is projected to rise significantly over the next decade. At the same time, supply chains remain heavily concentrated, with China controlling a substantial share of both mining and processing capacity.

This imbalance has prompted policy responses in North America and Europe, including funding initiatives and incentives aimed at developing domestic supply. In the United States, mechanisms such as the Defense Production Act have been used to direct capital toward critical mineral projects, while Canadian companies may also benefit from cross-border collaboration and funding eligibility.

Within this environment, exploration-stage projects such as Atikokan are being evaluated not only on geological merit but also on their potential role in diversifying supply chains. However, it is important to note that the project remains at an early stage. The current results define exploration targets rather than confirmed economic mineralization.

Powermax holds a portfolio of REE-focused properties across Canada and the United States, including projects in British Columbia and Wyoming. The Atikokan property, comprising 455 unpatented mining claims, represents one of its more advanced exploration efforts in terms of integrated data analysis.

The next phase of work is to focus on refining these targets through additional field studies and, potentially, initial drilling campaigns. Such steps will be necessary to determine whether the identified anomalies translate into continuous mineralized zones with economic potential.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

• At the core of Cardio Diagnostics’ approach is the use of artificial intelligence to integrate multi-omic data to provide a more comprehensive view of cardiovascular health.
• The company’s proprietary platform is designed to analyze a patient’s molecular profile from a single blood draw and generate actionable insights related to cardiovascular disease risk.
• CDIO’s focus on accessibility and scalability is also notable.

Cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. Cardio Diagnostics Holdings (NASDAQ: CDIO) is at the forefront of this shift, developing a proprietary platform that integrates epigenetic and genetic biomarkers with AI to generate personalized cardiovascular risk assessments from a simple blood sample.

At the core of Cardio Diagnostics’ approach is the use of AI to integrate multi-omic data, specifically epigenetic markers such as DNA methylation with genetic information, to provide a more comprehensive view of cardiovascular health. Traditional diagnostic tools often rely on population-based risk factors such as cholesterol levels, blood pressure and family history. While these indicators are valuable, they may not fully capture individualized disease risk or early molecular changes of disease that precede clinical symptoms. By contrast, epigenetic biomarkers reflect how environmental and lifestyle factors influence gene expression, offering a dynamic layer of insight that evolves over time.

The scientific foundation for this approach is well supported. Research published by the National Institutes of Health highlights that DNA methylation patterns can serve as sensitive indicators of disease risk and biological aging, with applications in cardiovascular conditions. These epigenetic modifications can reveal early disruptions in biological pathways long before structural changes or symptoms may appear, making them particularly valuable for preventive care and early intervention.

Cardio Diagnostics’ platform builds on this concept by combining epigenetic and genetic data with AI algorithms designed to detect complex patterns across large datasets. AI has increasingly been recognized as a powerful tool in healthcare for identifying relationships that may not be apparent through conventional statistical methods. A report from National Academy of Medicine notes that AI can enhance clinical decision-making by uncovering subtle correlations in biomedical data and improving risk prediction models. By applying machine learning to multi-omic inputs, Cardio Diagnostics aims to deliver more accurate and individualized assessments than traditional models.

The company’s proprietary platform is designed to analyze a patient’s molecular profile from a single blood draw and generate actionable insights related to cardiovascular disease risk. This approach simplifies the diagnostic process while improving precision. The use of a blood-based test is particularly important, as it reduces barriers to testing and enables broader accessibility compared to more invasive or resource-intensive diagnostic procedures.

The integration of multiple biomarker types is also a key differentiator. Genetic markers provide information about inherited set points in key biological pathways, while epigenetic markers capture real-time biological responses to factors such as diet, stress and environmental exposures. Together, these data layers create a more complete picture of cardiovascular health. 

This aligns with broader trends in precision medicine, where combining diverse data sources has been shown to improve predictive accuracy. The National Human Genome Research Institute emphasizes that both genomic and epigenomic research enhance the understanding of complex diseases and support more personalized approaches to care, including tailoring treatment based on individual molecular profiles.

Artificial intelligence serves as the analytical engine that makes this integration possible. Machine learning models can process high-dimensional datasets and continuously improve as more data becomes available. This capability is essential when working with epigenetic information, which can vary widely between individuals and over time. By training algorithms on large datasets, platforms such as the one developed by Cardio Diagnostics can identify patterns associated with disease risk or presence of disease and translate them into clinically relevant insights.

The company’s focus on accessibility and scalability is also notable. Blood-based diagnostics are among the fastest-growing segments in precision medicine, driven by their convenience and potential for early detection. A “Nature Medicine Journal” article reports that liquid biopsy approaches, which analyze biomarkers in blood, are increasingly being used to detect and monitor diseases with high sensitivity and specificity. While much of the early work has focused on oncology, similar principles are now being applied to cardiovascular disease, where early detection can significantly influence outcomes.

Cardio Diagnostics’ platform reflects a broader shift toward proactive health care, where the goal is not only to diagnose disease but to predict and prevent it. By leveraging epigenetic and genetic data, the company aims to move beyond static risk assessments and provide insights that evolve with the patient. This dynamic approach has the potential to support more timely interventions and better-informed clinical decisions.

In addition to its technological foundation, CDIO’s platform is designed to fit within existing health-care workflows. The simplicity of a blood test, combined with AI-driven analysis, allows for integration into routine care settings without requiring extensive new infrastructure. This is particularly important as healthcare systems increasingly seek solutions that can scale efficiently while maintaining high levels of accuracy and reliability.

As precision medicine continues to advance, the integration of multi-omic data and artificial intelligence is expected to play a central role in the future of diagnostics. Cardio Diagnostics Holdings is positioning itself within this emerging landscape by developing a platform that combines scientific rigor with practical usability. By translating complex molecular data into actionable insights, the company is contributing to a new generation of diagnostic tools aimed at improving how cardiovascular risk and disease are assessed and managed.

For more information, visit www.CDIO.ai.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

• Greenland Energy holds rights to up to 70% working interest across three onshore licenses covering more than 2 million acres in East Greenland’s Jameson Land Basin.
• Independent Sproule ERCE engineering estimates indicate recoverable oil upside of 13 billion barrels across the basin, which was extensively evaluated by ARCO decades ago but never drilled.
• The company has contracted Stampede Drilling for Arctic-rated rig services alongside agreements with Halliburton, Desgagnés, and IPT Well Solutions to support its 2026 drilling campaign.

Onshore basins of genuine scale that remain undrilled are increasingly rare. Most of the world’s major hydrocarbon-producing regions have been systematically tested over the past half-century, leaving frontier opportunities concentrated in geographies with challenging logistics, complex permitting, or historically limiting macroeconomic conditions. 

Where such basins remain, they carry a combination of technical risk and optionality that draws a specific type of investor interest. The Jameson Land Basin in East Greenland, a petroleum basin historically evaluated by US Atlantic Richfield Company (“ARCO”) but never drilled, represents one of the most prominent examples of that profile. Greenland Energy (NASDAQ: GLND) is the publicly traded platform now advancing it.

When they do emerge, these types of opportunities tend to represent outsized, binary-style outcomes where success or failure can redefine the value of an entire region.

The Jameson Land Basin Opportunity

The Jameson Land Basin covers more than 2 million acres in East Greenland and has been compared geologically to prolific hydrocarbon systems such as Prudhoe Bay in Alaska and the North Sea.

ARCO, following its discovery of the giant Prudhoe Bay oil field, invested the equivalent of more than $275 million in today’s dollars evaluating Jameson, conducting detailed field mapping, acquiring approximately 1,800 kilometers of 2D seismic data, and constructing the Constable Point Airfield that remains a key piece of regional infrastructure. Despite identifying substantial oil potential, the basin remained undrilled due to corporate strategy shifts and macroeconomic conditions rather than unfavorable technical findings.

Greenland Energy has reprocessed the legacy seismic data with modern technology, identifying more than 50 distinct oil and gas targets with structural and stratigraphic trapping potential. An independent Sproule ERCE engineering report indicates upside of 13 billion barrels of recoverable oil across the basin.

In practical terms, much of the early-stage geological risk has already been addressed, what remains is the execution risk of drilling a basin that has never been tested.

From Legacy Data to Public Market Platform

Greenland Energy was formed through the business combination of Pelican Acquisition Corporation, Greenland Exploration Limited, and March GL Company. The transaction closed March 25, 2026, with shares commencing trading on NASDAQ under the ticker symbol “GLND” the following day at an approximately $215 million implied valuation.

Under the structure, Greenland Energy holds rights to own up to 70% of three onshore licenses covering the entire petroleum basin, with working interest earned through a subsidiary of 80 Mile. ThinkEquity LLC served as financial advisor across the transaction.

The formation of a publicly traded platform provides access to capital markets at a stage where large-scale exploration programs require coordinated funding, technical execution, and long-term planning.

Operational Readiness and Partnerships

On March 27, 2026, Greenland Energy announced a five-year strategic drilling agreement with Stampede Drilling Inc. (TSX: SDI), securing Stampede’s Rig #12,  equipped for Arctic conditions, for upcoming operations in the Jameson Land Basin. Plans under the agreement call for drilling up to two wells.

The drilling contract is complemented by agreements with Halliburton for logistics planning and drilling services, Desgagnés for Arctic shipping of drilling equipment, and IPT Well Solutions as project manager providing additional oversight and technical support.

The Greenland Government has approved the mobilization and sealift landing of heavy equipment including a D9 bulldozer, trucks, excavators, loaders, generators, and housing units, which will support construction of a three-mile access road to the drilling site. A 3,500-meter-capable drilling rig has been secured for the program.

Taken together, these agreements move the project from conceptual to executable, a distinction that often defines the transition from narrative to measurable outcomes in frontier exploration.

Leadership and Capital Markets Perspective

Greenland Energy’s leadership includes Larry G. Swets, Jr. as Executive Chairman and Robert Price as Chief Executive Officer, with directors and executives drawn from the predecessor entities.

On March 26, 2026, the company appointed Joe Moglia, former Chief Executive Officer and Chairman of TD Ameritrade, as Executive Advisor to the Board. Moglia brings decades of capital markets and corporate strategy experience, including current roles as Chairman of Fundamental Global and Capital Wealth Advisors and Executive Advisor to FG Nexus.

His appointment adds a layer of capital markets perspective to a company transitioning from formation to execution.

Why the Timing Matters

Western energy security has become an explicit policy priority in recent years, with governments and capital markets increasingly focused on reducing dependence on geopolitically constrained supply sources. Greenland’s emergence as a strategic frontier aligns with that shift, and the Jameson Land Basin’s combination of scale, existing infrastructure, and regulatory progress positions Greenland Energy as an early mover in a region that has drawn attention but seen limited commercial activity.

“Our work in the Jameson Land Basin represents a rare opportunity to unlock one of the largest undrilled onshore basins in the Arctic through a disciplined, environmentally responsible approach,” said Robert Price, Chief Executive Officer of Greenland Energy.

With field activity progressing, equipment mobilization approved, and drilling partnerships in place, the company is moving toward what would be the first modern well drilled in a basin whose potential has been documented, but never tested, for more than four decades.

For more information, visit the company’s website at www.GreenlandEnergyCo.com.

NOTE TO INVESTORS: The latest news and updates relating to GLND are available in the company’s newsroom at ibn.fm/GLND

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF)and may include paid advertising.

• Planet Ventures provides shareholders with exposure to private space and aerospace companies through a publicly traded investment vehicle.
• The company employs a diversified portfolio strategy spanning infrastructure, software, energy, robotics, and emerging space applications.
• Its investment approach is positioned to benefit from the continued growth and commercialization of the global space sector.
• Recent activity includes investments in Relativity Space (via MCXGP), Antaris following its $28 million Series A financing, and General Astronautics, a Y Combinator Winter 2026 company.
• The company has also deployed capital into early-stage opportunities such as Mantis Space and GRU Space, reflecting a focus on emerging technologies across the space economy.

Planet Ventures (CSE: PXI) (OTC: PNXPF) is an investment issuer focused on identifying and investing in innovative companies operating within the space and aerospace sectors. The company’s strategy is centered on providing shareholders with exposure to emerging, high-growth opportunities, including private companies that are typically accessible primarily to venture capital and institutional investors.

The company employs a portfolio-driven investment approach, seeking to build a diversified base of investments across multiple segments of the space economy. Its activities are focused on sourcing and participating in opportunities globally, leveraging its network and experience to access and evaluate potential investments aligned with long-term growth trends in the sector.

Planet Ventures aims to create shareholder value through strategic capital allocation into companies developing technologies and services that support the expanding commercial space ecosystem.

The company is headquartered in Vancouver, British Columbia.

Portfolio

Planet Ventures operates as an investment platform, deploying capital into companies across the space and aerospace value chain, including infrastructure, software, energy, robotics, and emerging applications.

The company’s investment thesis is based on the view that many of the most significant opportunities in the space sector remain private and are not directly accessible to public market investors. Through its investment approach, Planet Ventures provides shareholders with indirect exposure to these companies, including through positions that may offer access to private businesses typically only available to venture capital and institutional investors.

Launch & Infrastructure

Planet Ventures has gained exposure to Relativity Space Inc. through an investment in MCXGP Relativity Fund I LLC, a special purpose vehicle that participated in the company’s most recent financing round. Relativity Space is developing reusable launch vehicles, including the Terran R rocket, designed for mid-to-heavy lift missions and low Earth orbit satellite deployment.

The company has also invested in Mantis Space Corp., which is developing orbital energy infrastructure intended to deliver power to satellites and other space-based systems.

Software & Data Platforms

Planet Ventures has made a strategic investment in Antaris Inc., an AI-powered platform designed to support the design, simulation, and operation of satellite constellations. The platform is intended to streamline mission development and enable software-driven approaches to space operations.

Emerging Applications & Robotics

Planet Ventures has invested in Galactic Resource Utilization Space Inc. (“GRU Space”), a company focused on developing habitat infrastructure for use beyond Earth, including concepts related to space tourism.

The company has also invested in General Astronautics, a space robotics company developing autonomous systems designed to operate in microgravity environments to support research and manufacturing activities in space.

Market Opportunity

Planet Ventures operates within the global space economy, which is valued at approximately $626 billion in 2025 and is projected to exceed $1.8 trillion by 2035, according to data from the World Economic Forum. Growth in the sector is being driven by increasing commercialization (with commercial revenues accounting for 78% of the total market, according to the Space Foundation), as well as expanding satellite applications, infrastructure development, and national security initiatives.

The space economy encompasses a wide range of activities that can be broadly divided into upstream and downstream segments. Upstream activities include launch systems, satellite manufacturing, and on-orbit operations, while downstream activities include satellite communications, navigation and positioning services, and earth observation.

The satellite segment represents a significant portion of the overall market, alongside growing areas such as space infrastructure, software platforms, and emerging commercial applications. Increased participation from private companies continues to play a central role in the expansion of the sector.

Leadership Team

Etienne Moshevich, Chief Executive Officer, has a background in capital markets and private investing and has focused on evaluating, financing, and advising early-stage and growth companies across multiple sectors. His role includes portfolio strategy, capital allocation, and investor relations, with a focus on aligning management teams and shareholders toward long-term outcomes.

Desmond Balakrishnan, Executive Director, is a partner at McMillan LLP and an experienced capital markets and securities lawyer. He has advised clients across multiple industries and has experience in private equity investments, public offerings, mergers and acquisitions, and listed company advisory.

Brian Shin, Chief Financial Officer, specializes in financial reporting, corporate finance, auditing, corporate strategy, and risk management. He provides accounting and consulting services to both public and private companies and has served as CFO for multiple organizations in Canada.

For more information, visit the company’s website at https://planetventuresinc.com.

NOTE TO INVESTORS: The latest news and updates relating to PNXPF are available in the company’s newsroom at https://ibn.fm/PNXPF

• Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies.
• Soligenix announced that the European Commission granted orphan drug designation to SGX945 for the treatment of Behçet’s disease.
• SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators.

Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug designation to its investigational therapy SGX945 for the treatment of Behçet’s disease, reinforcing both the promise of the therapy and the company’s broader development strategy.

Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies. Orphan drug designation in the European Union (“EU”) is specifically intended to encourage the development of treatments for rare diseases, which are defined as conditions affecting no more than five in 10,000 people in the EU. These designations provide important incentives, including protocol assistance, reduced regulatory fees and up to 10 years of market exclusivity following approval, all of which are designed to support the advancement of therapies that might otherwise face significant development barriers.

Such recognition also signals that a therapy addresses a condition with a high unmet medical need and demonstrates the potential to provide meaningful clinical benefit. The European Medicines Agency notes that orphan designation is granted when a product is intended to diagnose, prevent or treat a life-threatening or chronically debilitating condition and where existing treatment options are limited or inadequate. For companies such as Soligenix, this type of validation can help accelerate development, attract investment and enhance visibility within the global healthcare community.

The condition targeted by SGX945, Behçet’s disease, is a rare and chronic inflammatory disorder characterized by inflammation of blood vessels throughout the body. Behçet’s disease can cause recurring symptoms such as painful oral and genital ulcers, skin lesions and inflammation affecting multiple organ systems, and it may lead to serious complications depending on the organs involved. The disease is often relapsing in nature and can significantly impact quality of life, underscoring the need for effective and well-tolerated treatment options.

Against this backdrop, Soligenix announced that the European Commission, acting on a positive recommendation from the European Medicines Agency’s Committee for Orphan Medicinal Products, granted orphan drug designation to SGX945 (dusquetide) for the treatment of Behçet’s disease. This designation represents a key milestone in the development of the therapy and aligns with the company’s focus on addressing rare and difficult-to-treat conditions.

SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators. These molecules are designed to modulate the body’s immune response, promoting an anti-inflammatory and tissue-healing profile while enhancing the body’s ability to respond to infection. This mechanism represents a novel therapeutic approach for inflammatory and immune-mediated diseases, including Behçet’s Disease, where dysregulated immune activity plays a central role.

Orphan drug designation in the European Union provides a range of development and commercial advantages. These include eligibility for protocol assistance from the European Medicines Agency, access to centralized marketing authorization procedures and a 10-year period of market exclusivity upon approval, all of which are intended to support the successful development and commercialization of therapies for rare conditions.

In addition to its regulatory benefits, the designation reinforces the clinical rationale for SGX945. The therapy has demonstrated encouraging results in earlier studies, including improvements in oral ulcer outcomes among patients with Behçet’s disease and a favorable tolerability profile. These findings support continued development and suggest that the therapy may offer a meaningful alternative to existing treatment approaches.

The importance of SGX945 extends beyond a single indication. As part of Soligenix’s broader pipeline, the therapy reflects a platform-based approach that seeks to leverage scientific expertise across multiple programs targeting rare inflammatory and immune-related conditions. This strategy enables the company to pursue a range of therapeutic opportunities while maintaining a focused development framework.

The European Commission’s decision to grant orphan drug designation to SGX945 represents a meaningful step forward in that effort. By providing both regulatory support and commercial incentives, the designation helps position the therapy for continued advancement while highlighting its potential to address a significant unmet medical need. For patients living with Behçet’s Disease, where treatment options remain limited, such progress offers the possibility of improved outcomes and a better quality of life.

As Soligenix continues to advance its clinical programs, milestones such as this underscore the importance of collaboration between biotechnology innovators and global regulatory authorities. Together, these efforts play a critical role in bringing new therapies to patients with rare and challenging conditions, while reinforcing the value of scientific innovation in addressing unmet medical needs.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types
• First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity
• Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high

Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug regimens targeting different biological pathways are delivering results that single agents cannot.

Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) is advancing a first-in-class compound designed to fit directly into that model. Rather than developing a standalone therapy, the company is focused on enhancing the effectiveness of existing treatments, specifically chemotherapy and immunotherapy, across a broader range of patients.

The Case for Combination Oncology

The shift toward combination-based treatment reflects a fundamental biological reality. Cancer cells are highly adaptive. Therapies that target a single pathway often lose effectiveness as tumors evolve alternative survival mechanisms.

The industry response has been to combine therapies that act through different mechanisms simultaneously. This approach is gaining traction as clinical data continues to show improved response rates and durability when targeted therapies are paired with immunotherapy or traditional chemotherapy.

The pattern is consistent: treatments that both damage cancer cells directly and activate the immune system tend to outperform either strategy alone. Lixte’s development strategy is built around that premise.

How LB-100 Fits the Model

LB-100 is a small molecule inhibitor of protein phosphatase 2A (“PP2A”), an enzyme involved in regulating key cellular functions, including DNA repair. By inhibiting PP2A, the compound disrupts the ability of cancer cells to recover from treatment-induced damage, increasing their susceptibility to chemotherapy and radiation.

At the same time, LB-100 has demonstrated immune-related activity. It promotes cytokine production, increases T-cell proliferation, and enhances the generation of neoantigens, helping the immune system better recognize and attack tumor cells.

This dual mechanism positions LB-100 as a complementary agent within combination regimens, particularly alongside immune checkpoint inhibitors such as PD-1 therapies.

Supporting the biological rationale, external research has shown that tumors with PP2A-related mutations may respond more favorably to immunotherapy, reinforcing the potential role of PP2A inhibition in enhancing immune response.

Clinical Development Across High-Need Indications

Lixte is advancing LB-100 across multiple clinical programs focused on solid tumors with limited treatment options.

In ovarian clear cell carcinoma, the compound is being evaluated in combination with a PD-1 inhibitor in a Phase 1b/2 study, with patient enrollment ongoing. Additional trials are exploring LB-100 in metastatic microsatellite-stable colorectal cancer, a setting where traditional immunotherapy has historically shown limited effectiveness.

The company has also completed Phase 1b enrollment in a study combining LB-100 with chemotherapy in advanced soft tissue sarcoma, with data analysis underway. This represents a potential near-term catalyst as the first meaningful readout from its combination strategy in that indication.

Preclinical research, supported by more than 25 published studies, has demonstrated anti-cancer activity across multiple tumor types, while early-stage clinical trials have established a favorable safety profile without significant increases in toxicity when used alongside standard treatments.

Addressing the Limits of Current Therapies

The rationale for a treatment enhancer like LB-100 is rooted in the limitations of existing therapies. Chemotherapy and immunotherapy both face challenges, including resistance, inconsistent response rates, and toxicity constraints that limit dosing.

A compound capable of increasing tumor sensitivity while also improving immune system engagement addresses those challenges directly. Rather than replacing established therapies, the goal is to improve how effectively they work.

This approach also aligns with growing focus on the tumor microenvironment, where immune activation is increasingly viewed as a critical factor in long-term outcomes.

Positioned Within an Evolving Treatment Landscape

As oncology continues to move toward personalized, multi-drug treatment strategies, the role of complementary therapies is expanding. Companies developing agents that enhance existing treatments, rather than competing with them, are becoming an important part of that ecosystem.

Lixte’s focus on PP2A inhibition, supported by ongoing clinical development and a defined patent portfolio, reflects that positioning.

The company’s long-term opportunity is tied to the success of combination oncology itself. If multi-drug regimens continue to define the next generation of cancer treatment, therapies designed to amplify existing standards of care may play a meaningful role in improving patient outcomes.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT